Bolt Biotherapeutics, Inc.: RENAISSANCE TECHNOLOGIES LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Renaissance Technologies LLC amended its Schedule 13G filing for Bolt Biotherapeutics, Inc., disclosing a change in its passive stake in the clinical-stage immuno-oncology company. The amendment was filed with the SEC under accession number 0001037389-26-000063. The filing does not specify the size or direction of the stake change in the headline, leaving investors to review the full document for updated share counts and ownership percentages. The update matters because 13G amendments signal shifts in institutional positioning that can influence sentiment in a thinly traded small-cap biotech. Next, watch for the detailed filing to confirm whether Renaissance increased or reduced its position, and whether other institutional holders follow suit.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Bolt Biotherapeutics, Inc., Renaissance Technologies LLC